Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
21 mai 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
17 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
05 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
03 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
07 mars 2024 15h23 HE
|
PRISM MarketView
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
05 mars 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
20 févr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
20 déc. 2023 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry: for people affected by pelvic radiation during cancer treatment
10 mai 2022 15h27 HE
|
Lipella Pharmaceuticals, Inc.
Pittsburgh, Pennsylvania, United States , May 10, 2022 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. is announcing the Radiation Cystitis Patient Registry, an on-line patient registry program...